DUBLIN, IRELAND, May 01, 2018 -- Horizon Pharma plc (NASDAQ:HZNP), today announced that the company will participate in the following conference in May:
UBS Global Healthcare Conference
- Date: May 22, 2018
- Presentation Time: 9:30 a.m. ET
- Location: New York
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
| Contacts: | |
| Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] | U.S. Media: Geoff Curtis Senior Vice President, Corporate Affairs & Chief Communications Officer [email protected] |
| Ruth Venning Executive Director, Investor Relations [email protected] | Ireland Media: Ray Gordon Gordon MRM [email protected] |


Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Same sparkle, different story: how lab-grown diamonds are transforming the market
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Japan Earthquake Disrupts Auto and Chip Supply Chains
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 



